Limits...
Enhancement of calcium/vitamin d supplement efficacy by administering concomitantly three key nutrients essential to bone collagen matrix for the treatment of osteopenia in middle-aged women: a one-year follow-up.

Masse PG, Jougleux JL, C Tranchant C, Dosy J, Caissie M, P Coburn S - J Clin Biochem Nutr (2009)

Bottom Line: The three groups were comparable at baseline except for BMD.A loss of 2% was evidenced in the placebo group at one lumbar site.Although biomarkers of resorption did not change, hormone (PTH and 1,25(OH)(2)D(3))-induced osteoclastic activity was significantly reduced.

View Article: PubMed Central - PubMed

Affiliation: School of Food Science and Nutrition, Université de Moncton, Moncton, NB, E1A 3E9, Canada.

ABSTRACT
Two vitamins and proline (CB(6)Pro), three nutrients essential for bone collagen, were used in combination to a 1000 mg calcium/250 IU vitamin D (Ca/D) daily supplement to treat osteopenia as a preventive measure against osteoporosis later in life. Middle-aged women not using estrogen were screened for osteopenia using the WHO criteria and divided into three groups (n = 20 each): 1) placebo healthy controls with normal bone mineral density (BMD); 2) control Ca/D-treated osteopenic patients; and 3) Ca/D + CB(6)Pro-treated osteopenic patients. The three groups were comparable at baseline except for BMD. After one-year treatment, cortical diaphyseal BMD remained constant in each group, but trabecular bone loss persisted (at 5 lumbar sites) in osteopenic group 2. No further bone loss was detected in osteopenic group 3. A loss of 2% was evidenced in the placebo group at one lumbar site. Markers of bone formation (which increase in coupling to resorption) decreased significantly in both osteopenic groups. Although biomarkers of resorption did not change, hormone (PTH and 1,25(OH)(2)D(3))-induced osteoclastic activity was significantly reduced. No decline in BMD occurred at any bone site in osteopenic group 3, highlighting the importance of improving the quality of bone matrix concomitantly to mineral replacement.

No MeSH data available.


Related in: MedlinePlus

Pre- and post-treatment bone mineral density (BMD, g/cm2) at lumbar (A and B) and femoral (C) sites in each subject group (n = 20) for all sites under investigation. Pre- and post-treatment are indicated by plain and hatched bars, respectively. White, light grey and darker grey bars represent, respectively, the normal controls, the control osteopenic group treated with calcium/vitamin D, and the experimental osteopenic group treated with calcium/vitamin D combined with three other bone-related nutrients relevant to collagen matrix. Data are means ± SD. Neck: femur neck; Wards: femur Ward’s triangle; Troch: femur trochanter; Dia: femur diaphysis. Asterisks indicate significance levels for pre- and post-treatment comparisons for each group: *p<0.05; **p<0.01; ***p<0.001.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2803129&req=5

Figure 2: Pre- and post-treatment bone mineral density (BMD, g/cm2) at lumbar (A and B) and femoral (C) sites in each subject group (n = 20) for all sites under investigation. Pre- and post-treatment are indicated by plain and hatched bars, respectively. White, light grey and darker grey bars represent, respectively, the normal controls, the control osteopenic group treated with calcium/vitamin D, and the experimental osteopenic group treated with calcium/vitamin D combined with three other bone-related nutrients relevant to collagen matrix. Data are means ± SD. Neck: femur neck; Wards: femur Ward’s triangle; Troch: femur trochanter; Dia: femur diaphysis. Asterisks indicate significance levels for pre- and post-treatment comparisons for each group: *p<0.05; **p<0.01; ***p<0.001.

Mentions: BMD in the healthy control group having received a placebo did not change after one year, except that a significant 2% loss (p<0.05) at L1-L2 site occurred (Fig. 2B). Osteopenic patients treated with the conventional calcium/vitamin D supplement continued to lose bone minerals, to a much greater extent than the normal BMD controls, as shown by significant reductions in BMD at five lumbar sites (L3, L1-L2, L1-L3, L1-L4, L2-L3; significance levels indicated on Fig. 2A and B) at the end of the study. However, the femur neck BMD was significantly improved (p<0.05) (Fig. 2C). The combination of calcium/vitamin D with the three key collagen-related nutrients (vitamins C and B6 + proline) administered to osteopenic group 3 deterred further bone loss at all bone sites, at least during the one-year treatment period, compared to the results obtained in the two other groups, especially the other osteopenic group treated with calcium/vitamin D alone. Cortical diaphyseal bone remained constant in each group during the study.


Enhancement of calcium/vitamin d supplement efficacy by administering concomitantly three key nutrients essential to bone collagen matrix for the treatment of osteopenia in middle-aged women: a one-year follow-up.

Masse PG, Jougleux JL, C Tranchant C, Dosy J, Caissie M, P Coburn S - J Clin Biochem Nutr (2009)

Pre- and post-treatment bone mineral density (BMD, g/cm2) at lumbar (A and B) and femoral (C) sites in each subject group (n = 20) for all sites under investigation. Pre- and post-treatment are indicated by plain and hatched bars, respectively. White, light grey and darker grey bars represent, respectively, the normal controls, the control osteopenic group treated with calcium/vitamin D, and the experimental osteopenic group treated with calcium/vitamin D combined with three other bone-related nutrients relevant to collagen matrix. Data are means ± SD. Neck: femur neck; Wards: femur Ward’s triangle; Troch: femur trochanter; Dia: femur diaphysis. Asterisks indicate significance levels for pre- and post-treatment comparisons for each group: *p<0.05; **p<0.01; ***p<0.001.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2803129&req=5

Figure 2: Pre- and post-treatment bone mineral density (BMD, g/cm2) at lumbar (A and B) and femoral (C) sites in each subject group (n = 20) for all sites under investigation. Pre- and post-treatment are indicated by plain and hatched bars, respectively. White, light grey and darker grey bars represent, respectively, the normal controls, the control osteopenic group treated with calcium/vitamin D, and the experimental osteopenic group treated with calcium/vitamin D combined with three other bone-related nutrients relevant to collagen matrix. Data are means ± SD. Neck: femur neck; Wards: femur Ward’s triangle; Troch: femur trochanter; Dia: femur diaphysis. Asterisks indicate significance levels for pre- and post-treatment comparisons for each group: *p<0.05; **p<0.01; ***p<0.001.
Mentions: BMD in the healthy control group having received a placebo did not change after one year, except that a significant 2% loss (p<0.05) at L1-L2 site occurred (Fig. 2B). Osteopenic patients treated with the conventional calcium/vitamin D supplement continued to lose bone minerals, to a much greater extent than the normal BMD controls, as shown by significant reductions in BMD at five lumbar sites (L3, L1-L2, L1-L3, L1-L4, L2-L3; significance levels indicated on Fig. 2A and B) at the end of the study. However, the femur neck BMD was significantly improved (p<0.05) (Fig. 2C). The combination of calcium/vitamin D with the three key collagen-related nutrients (vitamins C and B6 + proline) administered to osteopenic group 3 deterred further bone loss at all bone sites, at least during the one-year treatment period, compared to the results obtained in the two other groups, especially the other osteopenic group treated with calcium/vitamin D alone. Cortical diaphyseal bone remained constant in each group during the study.

Bottom Line: The three groups were comparable at baseline except for BMD.A loss of 2% was evidenced in the placebo group at one lumbar site.Although biomarkers of resorption did not change, hormone (PTH and 1,25(OH)(2)D(3))-induced osteoclastic activity was significantly reduced.

View Article: PubMed Central - PubMed

Affiliation: School of Food Science and Nutrition, Université de Moncton, Moncton, NB, E1A 3E9, Canada.

ABSTRACT
Two vitamins and proline (CB(6)Pro), three nutrients essential for bone collagen, were used in combination to a 1000 mg calcium/250 IU vitamin D (Ca/D) daily supplement to treat osteopenia as a preventive measure against osteoporosis later in life. Middle-aged women not using estrogen were screened for osteopenia using the WHO criteria and divided into three groups (n = 20 each): 1) placebo healthy controls with normal bone mineral density (BMD); 2) control Ca/D-treated osteopenic patients; and 3) Ca/D + CB(6)Pro-treated osteopenic patients. The three groups were comparable at baseline except for BMD. After one-year treatment, cortical diaphyseal BMD remained constant in each group, but trabecular bone loss persisted (at 5 lumbar sites) in osteopenic group 2. No further bone loss was detected in osteopenic group 3. A loss of 2% was evidenced in the placebo group at one lumbar site. Markers of bone formation (which increase in coupling to resorption) decreased significantly in both osteopenic groups. Although biomarkers of resorption did not change, hormone (PTH and 1,25(OH)(2)D(3))-induced osteoclastic activity was significantly reduced. No decline in BMD occurred at any bone site in osteopenic group 3, highlighting the importance of improving the quality of bone matrix concomitantly to mineral replacement.

No MeSH data available.


Related in: MedlinePlus